Connect with us

BioPharma

Vision Energy Inc., (OTCMKTS: VIHDD) Promo Continues as Phase 1 of Vision Energy’s Green Energy Terminal in Vlissingen Inks Major Engineering Deal

Published

on

Vision Energy Inc., (OTCMKTS: VIHDD) is making a powerful run up the charts up another 7% on Friday on well over $2 million in dollar volume. The Company put out big news on Thursday announcing it has partnered with Linde Engineering, to deliver preliminary Front-End Engineering and Design (FEED) services to its Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands for Phase 1 of Vision Energy’s Green Energy Terminal via the Company’s subsidiary Evolution Terminals BV. Linde Engineering adds a lot of credibility to this deal; the Company is a global industrial gases and engineering company with 2021 sales of $31 billion. 

Speculators love the kind of run that VIHDD is making here, every single day it goes a little bit higher. Starting in the last few days of September Vision Energy stock has steadily been running northbound from around $4 pre-split to $32 pre-split or currently $16 per share after the 2 for 1 forward stock split on November 8. The ticker symbol will lose the extra D in 16 business days from now. Vision Energy has a history of explosive moves up the charts skyrocketing from $2.50 in December 2020, to highs of $50 per share in January 2021. That run however, ended very abruptly and the stock fell back to where it started. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Vision Energy Inc.,VisionH2 Announces Name Change and Forward Split (OTCMKTS: VIHD) is an integrated energy company developing assets and solutions for the commercial, industrial and transportation sectors. Leveraging its proven track-record in site and asset procurement, accelerating development and permitting processes, plant design, and grid integration to facilitate low-carbon energy production, supply and distribution. The Company pursues reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with the highest yield, and where possible, projects are designed to leverage existing gas and power infrastructure to integrate and facilitate import and or distribution of reduced-carbon energy to domestic and global supply chains. Vision Energy is a portfolio company of First Finance, a private equity investment group with offices in Zurich, London and Vancouver. 

Vision Energy’s 100% owned Vlissingen green hydrogen development project located in Vlissingen (Flushing) Netherlands is currently in its Phase 1 Development Plan designed for the construction of approximately 400,000 cubic meters (CBM) of renewable liquid bulk storage capacity comprising 150,000 CBM allocated to Green Ammonia, 180,000 CBM allocated to Renewable Methanol and 70,000 CBM allocated to Biofuels and Liquid Organic Hydrogen Carriers (LOHC). Phase 1 CAPEX is estimated at EUR €450 million, including jetty infrastructure.

Vision Energy Vlissingen is the Company’s launching project, and its focus is on the construction of a 25 MW green hydrogen plant in the Vlissingen Port area, in the province of Zeeland. 

Initial planning and pre-development work having been concluded, Vision Energy submitted the permit application to Vlissingen Municipality and Zeeland Province end of April. This hydrogen plant will produce H2 using electrolysis and will include storage, loading and distribution facilities for evacuating the H2. Initially the plant will produce up to 3,600 tonnes of green hydrogen annually, it is however capable of producing over double that quantity. Furthermore, the concept of the hydrogen plant allows for future expansion of up to at least 100 MW, potentially increasing H2 production to around 30.000 tonnes annually. 

The project site is strategically located on an industrial plot of 30.000m2 in the Vlissingen Oost industrial park. The site is accessible by road, rail and waterway to support the supply and distribution of green hydrogen to consumers in the region, as well as to neighboring industrial companies who are already planning on using green hydrogen to decarbonize their operations. The Vlissingen hydrogen plant also is located next to the Sloecentrale electricity generating plant creating potential synergies. 

Vision Energy’s 50% owned Terneuzen green hydrogen development project located in the North Sea Port of Terneuzen, Netherlands, in partnership with Virya Energy, is developing a 25 MW green hydrogen production facility with tube-trailer loading and integrated distribution facilities. This scalable platform allows the partnership to scale up production capacity at this Site to 75 MW.  At 25 MW the plant will produce up to 3.5 million kilograms of green hydrogen per year, and up to 10.5 million kilograms of H2 output at 75 MW. The Project Site is strategically located near existing high voltage power and gas infrastructure as well as large renewable power producing assets for the supply of green electrons and large industrial customers for future offtake of clean hydrogen. Less than 1,500 metres from the Project Site is the 150kV ground station of TenneT, the Dutch national high voltage grid operator, and less than 1,400 metres away is the connection point to the Yara-Dow-Zeeland Refinery Pipeline which may be repurposed for H2 transport to the Zeeland Refinery in future. Adjacent to the Project Site is the Ghent-Terneuzen Canal, providing water access to the major European Port of Ghent. VisionH2 and Virya plan to build the initial 25 MW electrolysis plant using proven, commercially available technology. Projected development costs for the initial phase of the project are estimated at €35 – €40 million. 

https://twitter.com/stockscan01/status/1590075102946803714

To Find out the inside Scoop on VIHDD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

On November 10 Vison Energy through its wholly-owned subsidiary Evolution Terminals BV, has partnered with Linde Engineering, to deliver preliminary Front-End Engineering and Design (FEED) services to the project for Phase 1 of Vision Energy’s Green Energy Terminal. Scope includes design and engineering of 150,000 cubic meters (CBM) of Green Ammonia (NH3) storage, truck and barge loading facilities, ship loading and unloading facilities, and utilities, infrastructure and buildings, to accelerate engineering efforts for the Company’s pioneering Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands. Engineering efforts under the agreement have commenced and are anticipated to conclude in April 2023 in support of the Company’s target to reach Final Investment Decision (FID) by Q3 2023. 

Vision Energy is in the advanced stages of planning for the construction and delivery of Northwestern Europe’s first import, storage and handling terminal designed exclusively for hydrogen carriers, renewable energy products and low-carbon fuels. The Company is scheduled to file all remaining environmental and construction permits by December 2022. Total capacity under Phase 1 is for up to 400,000 CBM including 150,000 CBM allocated to Green Ammonia, 180,000 CBM allocated to Renewable Methanol and 70,000 CBM allocated to Biofuels. Linde is a leading global industrial gases and engineering company with 2021 sales of $31 billion (€26 billion). We live our mission of making our world more productive every day by providing high-quality solutions, technologies and services which are making our customers more successful and helping to sustain and protect our planet. 

Vision Energy CEO Andrew Hromyk stated: “Our cooperation with Linde Engineering marks a critical milestone in our development, to deliver this world-class project with the vast global expertise Linde possesses. Our Green Energy Terminal Project will accelerate and advance the energy transition and facilitate Northwestern Europe’s ambition to achieve Net Zero through carbon-abatement and adoption of hydrogen as a core feedstock and fuel.” 
John van der Velden, Senior Vice President Global Sales & Technology at Linde Engineering said: “We are proud to work with Vision Energy on the sustainable development of this ammonia terminal, leveraging our extensive EPC expertise and clean energy technology to enable the green hydrogen economy.”  

 For More on Vison Energy Subscribe Right Now!

Currently trading at a $620 million market valuation Vision Energy is a fully reporting SEC filer OTCQB with $5.5 million in the treasury and is virtually debt free with no convertible debt on the books. The stock has been rocketing northbound over the past week as the Company has put out a number of press releases as things ramp up for its 100% owned Green Energy Hub development project in the North Sea Port of Vlissingen, the Netherlands. This is a massive project; Phase 1 CAPEX is estimated at EUR €450 million, including jetty infrastructure. However, Vision Energy is being promoted and currently the Company does not have the assets to justify this valuation and while the slow steady rise every single day is great, one day the stock could crash, and when it does it could drop very, very quickly. As we said in our last article the stock made a spectacular run back in January 2021 from $2.50 to $50 in a month and is embarking on another big run now which may end similar to the last move which went very high very quickly but dropped just as fast when the promotion ended. Vision Energy will be trading as VIHDD for the next 16 trading days, after which the Company will be assigned a new ticker symbol. We will continue to report on this situation as it unfolds and more information becomes available. We will be updating on VIHDD when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in VIHDD either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.